Axillary Microbiota is Associated with Cognitive Impairment in Parkinson’s Disease Patients - Arikan, Muzaffer; Yildiz, Zeynep; Demir, Tugce Kahraman; Yilmaz, Nesrin H.; Sen, Aysu; Hanoglu, Lutfu; Yildirim, Suleyman (medRxiv, 2021)
Introduction Cognitive impairment (CI) is among the most common non-motor symptoms of Parkinson’s disease (PD) with substantially negative impact on patient management and outcome. The development and progression of CI exhibits high interindividual variability which requires better diagnostic and monitoring strategies. PD patients often display sweating disorders resulting from autonomic dysfunction which has been associated with CI. As the axillary microbiota is known to change with humidity level and sweat composition, we hypothesized that axillary microbiota of PD patients shifts in association with CI progression thus can be used as proxy for classification of CI stages in PD.Methods We compared the axillary microbiota compositions of 103 PD patients (55 PD patients with dementia (PDD) and 48 PD patients with mild cognitive impairment (PD-MCI)) and 26 cognitively normal healthy controls (HC).Results We found that axillary microbiota profiles differentiate HC, PD-MCI and PDD groups based on differential ranking analysis and detected an increasing trend in the log ratio of Corynebacterium to Anaerococcus in progression from HC to PDD. In addition, phylogenetic factorization revealed that the depletion of Anaerococcus, Peptoniphilus and W5053 genera is associated with PD-MCI and PDD. Moreover, functional predictions suggested significant increase of myo-inositol degradation, ergothioneine biosynthesis, propionate biosynthesis, menaquinone biosynthesis, and the proportion of aerobic bacteria and biofilm formation capacity in parallel to CI.Conclusion Our results suggest that alterations in axillary microbiota are associated with CI in PD. Thus, axillary microbiota holds potential to be exploited as a non-invasive biomarker in the development of novel strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a grant to Dr. Suleyman Yildirim from the Scientific and Technological Research Council of Turkey (TUBITAK) [grant number 315S301].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Istanbul Medipol University gave ethical approval for this work (authorization number 10840098-604.01.01-E.3958).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequence data produced in this study have been deposited in the NCBI Sequence Read Archive database under accession number PRJNA761243.